Adma Biologics (ADMA) Long-Term Deferred Tax (2012 - 2026)
Adma Biologics' (ADMA) quarterly Long-Term Deferred Tax came in at $73.3 million in Q4 2025, down 13.07% YoY from $84.3 million in Q4 2024, and down 1.57% on a QoQ basis from $74.4 million in Q3 2025.
Adma Biologics (ADMA) Long-Term Deferred Tax (2012 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 6 years of Long-Term Deferred Tax data on file, last reported at $73.3 million in Q4 2025.
- Quarterly Long-Term Deferred Tax fell 13.07% year-over-year to $73.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $73.3 million (down 13.07% YoY) and the FY2025 annual result came in at $73.3 million, down 13.07% from the prior year.
- Long-Term Deferred Tax eased to $73.3 million in Q4 2025, from $74.4 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $84.3 million in Q4 2024 to a low of $73.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69.97 Mn |
| Dec 31, 2025 | 73.26 Mn |
| Sep 30, 2025 | 74.43 Mn |
| Jun 30, 2025 | 79.24 Mn |
| Mar 31, 2025 | 80.86 Mn |
| Dec 31, 2024 | 84.28 Mn |
| Dec 31, 2018 | 624,610.00 |
| Dec 31, 2015 | 1.02 Mn |
| Mar 31, 2013 | 245,416.00 |
| Dec 31, 2012 | 363,403.00 |